SCHEMBL17434239

SCHEMBL17434239

CCn1c(=O)c2nc(Br)ccc2n(CC)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 3/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
GFER P55789 1/20 0.41
CYP1A2 P05177 2/20 0.39
ADORA2A P29274 3/20 0.38
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
ADORA2B P29275 3/20 0.37
ADORA1 P30542 3/20 0.37
HPGD P15428 2/20 0.37
MAPK1 P28482 2/20 0.37
HSD17B10 Q99714 2/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
THPO P40225 1/20 0.37
PMP22 Q01453 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17434075 0.81 ALDH1A1 (0.49) ALDH1A1KDM4EGAAMAPTGFER
SCHEMBL17434362 0.73 ADORA2A (0.45) ALDH1A1KDM4ECYP1A2ADORA2APDE4A
SCHEMBL18336768 0.73 KDM4E (0.39) ALDH1A1KDM4EGAAMAPTCYP1A2
SCHEMBL4551428 0.72 CMA1 (0.45) ALDH1A1KDM4EGAAMAPTGFER
SCHEMBL17433854 0.72 CYP1A2 (0.49) ALDH1A1MAPTCYP1A2ADORA2APDE4A
SCHEMBL28659735 0.71 PDE4A (0.41) MAPTADORA2APDE4APDE4BPDE4C
SCHEMBL31586409 0.70 PDE1A (0.31)
SCHEMBL17434513 0.69 PARG (0.50) ALDH1A1KDM4EGAAMAPTGFER
SCHEMBL18335903 0.69 MEN1 (0.36) ALDH1A1KDM4EMAPTCYP1A2HPGD
SCHEMBL29209040 0.67 ALDH1A1 (0.61) ALDH1A1KDM4EGAAMAPTGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834520-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-12-05 US disclosed
US-20160229814-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-08-11 US disclosed
EP-2975031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229814-A1 HETEROCYCLIC COMPOUND RORB, RORC, RORA ALDH1A1 312/4885KDM4E 728/4885GAA 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.